Variables | MPH | MH | SH | Total |
Number (%) | 17 142 (88.1) | 9534 (85.3) | 4869 (81.6) | 31 545 (86.2) |
Age (years), mean (SD) | 60.5 (12.3) | 60.0 (12.9) | 61.7 (14.0) | 60.5 (12.8) |
Caucasian, N (%) | 17 084 (99.66) | 9505 (99.70) | 4864 (99.90) | 31 453 (99.71) |
Height (cm), mean (SD) | 160.3 (6.5) | 160.5 (6.7) | 160.3 (6.9) | 160.4 (6.6) |
Weight (kg), mean (SD) | 68.8 (13.9) | 67.9 (14.1) | 68.0 (14.2) | 68.4 (14.0) |
BMI (kg/m2), mean (SD) | 26.8 (5.2) | 26.3 (5.2) | 26.5 (5.3) | 26.6 (5.2) |
Postmenopausal, N (%) | 12 420 (72.5) | 5856 (61.4) | 4024 (82.6) | 22 300 (70.7) |
Hormone replacement, n (%) | 1167 (6.8) | 326 (3.4) | 66 (1.4) | 1559 (4.9) |
Smokers, N (%) | 2094 (12.2) | 763 (8.0) | 67 (1.4) | 2924 (9.3) |
Family history osteoporosis, N (%) | 3563 (20.8) | 956 (10.0) | 60 (1.2) | 4579 (14.5) |
Corticosteroid use, N (%) | 1744 (10.2) | 1081 (11.3) | 179 (3.7) | 3004 (9.5) |
Prior fracture, N (%) | 4636 (27.0) | 2460 (25.8) | 1473 (30.2) | 8569 (27.2) |
Mean number comorbidities, mean (SD)* | 1.55 (0.81) | 1.43 (0.71) | 1.77 (0.93) | 1.6 (0.8) |
Frail, N (%) | 128 (0.8) | 37 (0.4) | 171 (3.5) | 336 (1.1) |
Prior falls, N (%) | 93 (0.5) | 97 (1.0) | 114 (2.3) | 304 (1.0) |
Calcium and/or vitamin D use, N (%) | 4492 (26.2) | 1902 (20.0) | 1048 (21.5) | 7442 (23.6) |
Osteoporosis medication use, N (%)† | 1649 (9.6) | 1034 (10.9) | 633 (13.0) | 3316 (10.5) |
Number of other medications, mean (SD)‡ | 1.06 (0.24) | 1.03 (0.16) | 1.10 (0.33) | 1.07 (0.26) |
FN BMD (g/cm2), mean (SD) | 0.839 (0.139) | 0.843 (0.138) | 0.846 (0.139) | 0.842 (0.139) |
FN T-score, mean (SD)§ | −1.1 (1.2) | −1.1 (1.1) | −1.1 (1.2) | −1.1 (1.2) |
Whole body fat mass (kg), mean (SD) | 19.02 (11.7) | 29.21 (12.3) | 19.7 (11.4) | 26.3 (12.8) |
Lean body mass (kg), mean (SD) | 35.95 (7.1) | 39.14 (5.5) | 35.5 (6.3) | 38.1 (6.0) |
Absolute risk of major osteoporotic fracture, median (IQR)¶ | 11.1 (9.53) | 10.6 (9.13) | 11.2 (9.32) | 11.03 (9.4) |
Absolute risk of hip fracture, median (IQR)¶ | 1.69 (3.54) | 1.65 (3.36) | 1.91 (3.69) | 1.73 (3.55) |
*Refers to other recorded medical illnesses/conditions.
†Refers to non-oestrogen therapies: bisphosphonates, SERMs (including raloxifene, SERM, Evista, Tibolone), strontium, denosumab, parathyroid hormone (anabolic).
‡Refers to mean number of other recorded medications being taken by an individual patient.
§FN T-score calculated using NHANES III white female reference.
¶Refers to 10-year risk of MOF calculated from age and BMD, or FRAX. Older technology calculated 10-year risk based on age and BMD using a proprietary algorithm derived from a Swedish 10-year risk prediction model. All machines have been updated to provide a FRAX estimate in the past 5 years.
BMD, bone mineral density; FN, femoral neck; FRAX, Fracture Risk Assessment Tool; LVA, lateral vertebral assessment; MH, Manorhamilton Hospital; MOF, major osteoporotic fracture; MPH, Merlin Park Hospital; N (%), number (percentage); NHANES, National Health and Nutrition Examination Survey; SD, standard deviation; SERM, selective oestrogen receptor modulator; SH, Sligo Hospital.